Join us in revolutionizing chronic pain treatment with proven, non-opioid solutions that address a critical, underserved market.
Alyea Therapeutics is poised to redefine chronic pain treatment with its innovative non-opioid solutions. With LDN progressing through regulatory approval and the Alyea Clear Patch technology expanding market opportunities, the company is at a pivotal stage for growth.
Investors have a unique opportunity to support a breakthrough approach to pain management that addresses a critical, underserved market.
LDN is a non-opioid treatment that works by modulating pain pathways and reducing inflammation rather than masking symptoms. Unlike opioids, it has no risk of addiction or dependence and provides long-term relief without severe side effects.
LDN has received FDA orphan drug designation for the treatment of Complex Regional Pain Syndrome (CRPS) and is currently advancing through clinical trials toward full regulatory approval. LDN is NOT FDA approved and Alyea’s version is still investigational and in clinical trials.
Alyea Clear Patch is a topical pain relief technology designed for targeted, localized treatment. It delivers non-invasive pain relief that is customizable to the location of pain. It allows for localized treatments without a lot of systemic absorption.
Alyea’s solutions are designed for patients suffering from chronic pain conditions such as CRPS for LDN and other inflammatory pain disorders for the clear patch, especially those seeking non-opioid alternatives.
Invest in innovative, non-opioid treatments that address a critical, underserved market.
Get In Touch
